# US 2003/0069207 A1 · Tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0069207 A1
- Document ID: US20030069207A1
- Status: Published application
- Kind: A1
- Application number: 10/237,918
- Filed: 2002-09-09
- Published: 2003-04-10
- Earliest claimed: 2001-09-07
- Assignees: Boehringer Ingelheim Pharma GmbH & Co. KG
- Inventors: Christine Votteler; Bernd Kruss
- Web page: https://patentgrep.com/patent/US20030069207A1

## CPC

- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/28: Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
- A61K 47/40: Cyclodextrins; Derivatives thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to new formulations for improving the local tolerance of intravenously administered 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine or one of the pharmacologically acceptable acid addition salts thereof.

## Claims

### Claim 1

A pharmaceutical composition comprising a mixture or a complex, or both, of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine, or one of the pharmacologically acceptable acid addition salts thereof, and a pharmacologically acceptable cyclodextrin.

### Claim 2 (depends on 1)

A pharmaceutical composition according to claim 1, wherein the pharmacologically acceptable cyclodextrin is a pharmacologically acceptable substituted β-cyclodextrin.

### Claim 3 (depends on 1)

A pharmaceutical composition according to claim 1, wherein the pharmacologically acceptable cyclodextrin is HPβCD.

### Claim 4

A pharmaceutical composition comprising a mixture or a complex, or both, of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine, or one of the pharmacologically acceptable acid addition salts thereof, a pharmacologically acceptable cyclodextrin and a hydroxy acid.

### Claim 5 (depends on 4)

A pharmaceutical composition according to claim 4, wherein the pharmacologically acceptable cyclodextrin is a pharmacologically acceptable substituted β-cyclodextrin.

### Claim 6 (depends on 4)

A pharmaceutical composition according to claim 4, wherein the pharmacologically acceptable cyclodextrin is HPβCD.

### Claim 7 (depends on 6)

A pharmaceutical composition according to claim 6, wherein the hydroxy acid is malic acid, acetic acid, lactic acid, tartaric acid or citric acid.

### Claim 8 (depends on 7)

A pharmaceutical composition according to claim 7, where the hydroxy acid is citric acid.

### Claim 9

A pharmaceutical composition comprising 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine, or one of the pharmacologically acceptable acid addition salts thereof, enveloped in a pharmaceutically acceptable polymer.

### Claim 10 (depends on 9)

A pharmaceutical composition according to claim 9, wherein the polymer is a poloxamer, polyvinylpyrrolidone or polysorbate.

### Claim 11 (depends on 9)

A pharmaceutical composition according to claim 9, wherein the polymer is Poloxamer 188 or PVP 17 PF.

### Claim 12

A pharmaceutical composition comprising 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine, or one of the pharmacologically acceptable acid addition salts thereof, incorporated in mixed micelles comprising a phospholipid and a bile salt.

### Claim 13 (depends on 12)

A pharmaceutical composition according to claim 12, wherein the phospholipid is soya lecithin and the bile salt is a sodium salt of cholic acid or glycocholic acid.

### Claim 14 (depends on 1)

A pharmaceutical composition according to claim 1, wherein the cyclodextrin improves the local tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine or one of the pharmacologically acceptable acid addition salts thereof.

### Claim 15 (depends on 4)

A pharmaceutical composition according to claim 4, wherein the cyclodextrin and hydroxy acid improve the local tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine or one of the pharmacologically acceptable acid addition salts thereof.

### Claim 16 (depends on 9)

A pharmaceutical composition according to claim 9, wherein the polymer improves the local tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine or one of the pharmacologically acceptable acid addition salts thereof.

### Claim 17 (depends on 12)

A pharmaceutical composition according to claim 12, wherein the phospholipid and bile salt improve the local tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine or one of the pharmacologically acceptable acid addition salts thereof.

### Claim 18 (depends on 1)

A pharmaceutical composition according to claim 1, in a form suitable for intravenous administration.

### Claim 19 (depends on 18)

A pharmaceutical composition according to claim 18, wherein the 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine, or one of the pharmacologically acceptable acid addition salts thereof, is present in a concentration of between 0.6 mg/ml and 40 mg/ml.

### Claim 20 (depends on 4)

A pharmaceutical composition according to claim 4, in a form suitable for intravenous administration.

### Claim 21 (depends on 20)

A pharmaceutical composition according to claim 20, wherein the 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine, or one of the pharmacologically acceptable acid addition salts thereof, is present in a concentration of between 0.6 mg/ml and 40 mg/ml.

### Claim 22 (depends on 9)

A pharmaceutical composition according to claim 9, in a form suitable for intravenous administration.

### Claim 23 (depends on 22)

A pharmaceutical composition according to claim 22, wherein the 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine, or one of the pharmacologically acceptable acid addition salts thereof, is present in a concentration of between 0.6 mg/ml and 40 mg/ml.

### Claim 24 (depends on 12)

A pharmaceutical composition according to claim 12, in a form suitable for intravenous administration.

### Claim 25 (depends on 24)

A pharmaceutical composition according to claim 24, wherein the 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine, or one of the pharmacologically acceptable acid addition salts thereof, is present in a concentration of between 0.6 mg/ml and 40 mg/ml.

### Claim 26 (depends on 1)

A method for treating acute myocardial infarction in a patient, comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition according to claim 1.

### Claim 27 (depends on 4)

A method for treating acute myocardial infarction in a patient, comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition according to claim 4.

### Claim 28 (depends on 9)

A method for treating acute myocardial infarction in a patient, comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition according to claim 9.

### Claim 29 (depends on 12)

A method for treating acute myocardial infarction in a patient, comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition according to claim 12.

### Claim 30 (depends on 1)

A method for treating a patient undergoing a coronary artery bypass operation, comprising administering to said patient a pharmaceutical composition according to claim 1.

### Claim 31 (depends on 4)

A method for treating a patient undergoing a coronary artery bypass operation, comprising administering to said patient a pharmaceutical composition according to claim 4.

### Claim 32 (depends on 9)

A method for treating a patient undergoing a coronary artery bypass operation, comprising administering to said patient a pharmaceutical composition according to claim 9.

### Claim 33 (depends on 12)

A method for treating a patient undergoing a coronary artery bypass operation, comprising administering to said patient a pharmaceutical composition according to claim 12.
